Detalhe da pesquisa
1.
Human anti-nucleolin recombinant immunoagent for cancer therapy.
Proc Natl Acad Sci U S A
; 112(30): 9418-23, 2015 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-26170308
2.
Mutated beta-catenin evades a microRNA-dependent regulatory loop.
Proc Natl Acad Sci U S A
; 108(12): 4840-5, 2011 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-21383185
3.
Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Cancers (Basel)
; 13(18)2021 Sep 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34572907
4.
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Oncotarget
; 14: 837-838, 2023 Sep 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37747363
5.
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.
Oncotarget
; 7(1): 224-40, 2016 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-26325594
6.
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Oncotarget
; 6(31): 31134-50, 2015 Oct 13.
Artigo
Inglês
| MEDLINE | ID: mdl-26429859
7.
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
J Exp Med
; 210(5): 951-68, 2013 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-23610125
8.
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
J Exp Med
; 214(5): 1557, 2017 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28104811
9.
Oncogenic role of miR-483-3p at the IGF2/483 locus.
Cancer Res
; 70(8): 3140-9, 2010 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20388800